Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹237 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
₹37.9 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Gufic BioSciences reported Q2 FY26 revenue of ₹230 crore (flat QoQ) and EBITDA of ₹37.9 crore (margin 16.45%, up 182bps QoQ). PAT came in at ₹14.9 crore (margin 6.47%). The Indore facility is scaling, with 40 products transferred and 27 under development; EBITDA breakeven is expected by Q4 FY26. Domestic branded formulations grew modestly, with infertility and toxin platforms leading at 18% and 22% YoY respectively. International business grew ~32% YoY, aided by new market entries. Management guided for Indore to become margin-accretive by FY27 and for CMO revenue to pick up from Q3. Key risk: CMO transition to Indore is slower than expected, delaying revenue ramp-up.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects the Indore facility to achieve EBITDA breakeven by Q4 FY26, with margin-accretive operations from FY27 onwards.
- At 70-80% capacity utilization, Indore can generate ₹750-800 crore in revenue, implying significant upside from current run-rate.
- Total borrowings (including working capital) of ~₹350-360 crore expected to reduce to ~₹300 crore in two years, with no major capex planned.
- GLP-1 contract manufacturing with Hetero expected to start contributing revenue from Q1 FY27, post patent expiry in March 2026.
Risks flagged
- CMO clients are slow to shift to Indore due to audit and validation requirements; only 4 of 12-14 major clients onboarded so far.
- Q2 revenue was flat QoQ despite higher volumes, as lower-priced products (e.g., pantoprazole, vancomycin) replaced higher-priced ones (e.g., teicoplanin).
- API price pass-through is eroding top-line growth in critical care and SPAR, with value growth of only 5-6% despite higher unit growth.
- EU GMP and UK MHRA audits targeted for Q1 FY27, but USFDA timeline remains uncertain; any delay could impact international revenue ramp-up.
Key quotes
- We are focusing on three things: indoor, dual chamber bag, and botulinum toxin. Let's get the debt off the books, go for a top line, and increase the margins.
- The entire bandwidth to create a new facility again would put us into some sort of a capital investment for the next two years... let's focus on what we already have.
- In the next two years, we will not have any major capex plan. Whatever additional working capital is required for Indore, we will generate from internal revenue.
Research modules